Post-earnings recap
Reported
Wed, Apr 28, 2021
Est. EPS
—
Est. revenue
—
Implied move
—
EPS beat rate
25%
—
Est. EPS
—
Est. Rev
—
Impl. Move
—
Viking Therapeutics reported a loss per share that was slightly worse than expected, but the stock still rose by 2.09%. This increase may reflect investor confidence in the company's ongoing clinical trials and future potential. The lack of revenue figures and guidance indicates uncertainty, but management's focus on research and development suggests they are prioritizing long-term growth.
| Metric | Actual | Expected | Surprise |
|---|---|---|---|
| EPS | $-0.19 | N/A | -7.95% |
| Revenue | N/A | N/A | N/A |
Management expressed a cautious optimism about their pipeline and future projects. They reiterated their commitment to advancing their clinical programs.
Management highlighted ongoing clinical trials and their importance for future growth.
They emphasized the need for continued investment in research and development.